Detection of minimal residual disease in acute myeloid leukemia.

被引：8
作者：
Baer M.R. [1 ]
机构：
[1] Leukemia Section, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, 14263, NY
来源：
Current Oncology Reports | 2002年 / 4卷 / 5期
关键词：
Acute Myeloid Leukemia; Residual Disease; Acute Promyelocytic Leukemia; Minimal Residual Disease; Acute Myeloid Leukemia Patient;
D O I：
10.1007/s11912-002-0033-z
中图分类号：
学科分类号：
摘要：
Acute myeloid leukemia (AML) is a curable malignancy, but its cure rate remains disappointingly low. Accurate quantitation of residual AML cells would allow individualization of therapy and thereby increase the likelihood of cure for each patient. Techniques that are being studied for residual disease detection include molecular assays for abnormalities that are present in subsets of AML patients, and multiparameter flow cytometry, which has broader applicability. Although significant advances have been made in the development of assays for monitoring residual disease, and particularly in techniques for molecular quantitation, additional refinement and validation are needed before these assays can be applied routinely in clinical management.
引用
收藏
页码：398 / 402
页数：4
相关论文
共 77 条
[11]  
Tobal K(2001)Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia Leukemia 15 1072-1080
[12]  
Moore H(2001)Detection and quantification of CBFB/MYH11 fusion transcripts in patients with inv(16)-positive acute myeloblastic leukemia by real-time RT-PCR Genes Chromosomes Cancer 30 342-348
[13]  
Macheta M(2002)Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state Blood 99 443-449
[14]  
Yin JAL(2001)Prevalence and prognostic significance of FLT3 internal tandem duplication in pediatric acute myeloid leukemia Blood 97 89-94
[15]  
Slack JL(2001)The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials Blood 98 1752-1759
[16]  
Bi W(2001)FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia Blood 97 3589-3595
[17]  
Livak KJ(2001)Quantitative, real-time polymerase chain reactions for FLT3 internal tandem duplications are highly sensitive and specific Leuk Res 25 1085-1088
[18]  
Tobal K(1997)Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia N Engl J Med 336 317-323
[19]  
Newton J(1996)Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels Blood 88 2267-2278
[20]  
Macheta M(2001)Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms’ tumour gene (WT1) mRNA: implications for monitoring human leukaemias Br J Haematol 114 313-318
12345678